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tions during trastuzumab infusions (n = 3, 6%). Hyperten-
sion, obesity, prior anthracyclines exposure and concurrent 
chemotherapy were associated with a higher incidence of 
toxic events. Previous radiotherapy, concurrent endocrine 
therapy and different trastuzumab-based regimens did not 
seem to influence toxicity.  Conclusions: Our data suggest 
that trastuzumab has a good safety profile in nonfrail wom-
en aged 70 years and older. These favorable findings may be 
related to a limited number of anthracycline pretreatments, 
patient selection and a close cardiologic monitoring. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Increasing age represents the main risk factor for de-
veloping breast cancer (BC). In the USA, its incidence has 
been reported to rise from 1 in 209 for women younger 
than 40 years to 1 in 14 for women aged 70 years  [1] . The 
number of breast cancers diagnosed in women >70 years 
old in the majority of Western countries has increased 
during the last decades  [2, 3] with further growth expect-
ed in the forthcoming decades  [4] . This is mostly attribut-
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 Abstract 
 Background: Breast cancer in the elderly is associated with 
high recurrence and death rates, due mostly to undertreat-
ment. Human epidermal growth factor receptor type 2 
(HER2) overexpression is infrequent in older patients. Trastu-
zumab-based chemotherapy is often withheld from elderly 
patients because of its cardiotoxicity.  Patients and Meth-
ods: Medical records of consecutive HER2-positive breast 
cancer patients aged  ≥ 70 years old treated between 2005 
and 2010 in the participating centers were retrospectively 
reviewed. All patients underwent multidimensional geriatric 
assessment (MGA).  Results: Among 59 patients identified, 
51 patients were evaluable (median age 76 years). The rate 
of any adverse event was 20% (10/51). The most relevant car-
diac adverse event consisted of symptomatic congestive 
heart failure (CHF; n = 1, 2%) followed by asymptomatic de-
creases of left ventricular ejection fraction (LVEF; n = 6, 12%). 
Other toxicities included moderate hypersensitivity reac-
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able to the population aging and to a larger use of screen-
ing mammography in elderly women  [5] . A more fre-
quent early detection, with consequent treatment of the 
disease at lower stages, has resulted in a progressive de-
cline in mortality  [3] . However, the survival gain has been 
slighter than in younger women  [6] , mainly due to under-
treatment; therefore, to date, the death rates for breast 
cancer remain high in this age group, reaching 41.7% in 
very elderly patients  [7] .
 The overexpression of the human epidermal growth 
factor receptor type 2 (HER2) has a negative impact on 
clinical outcomes  [8] . The frequency of HER2 positivity 
decreases with age. In a retrospective study on 2,723 con-
secutive patients, HER2-positive disease declined from 
27% in patients <40 years of age to 7% in patients >70 
years of age  [9] .
 Trastuzumab, a monoclonal antibody against the ex-
tracellular domain of HER2, has shown activity in meta-
static BC as monotherapy  [10] and remarkable efficacy in 
both metastatic and early-stage BC in combination with 
chemotherapy (CT), reducing relapse rates by 50% re-
gardless of age and other relevant prognostic factors  [11–
15] . These results were confirmed in several large, ran-
domized studies, which reported a significantly longer 
time to progression and overall survival with the combi-
nation of adjuvant trastuzumab plus CT, compared with 
CT alone  [12, 13, 16, 17] .
 Although trastuzumab, either alone or combined 
with CT in a weekly or 3-weekly regimen, is a well-estab-
lished standard treatment for early or advanced HER2-
positive breast cancer, the risk-benefit ratio of trastu-
zumab-based regimens in the elderly has not yet been 
defined, as in clinical trials there are no sufficient safety 
data on women aged 70 years and older. Indeed, this age 
cohort has been poorly enrolled  [18, 19] and mostly rep-
resented by healthy subjects. As a consequence, optimal 
treatment is controversial and, to date, the assessment of 
the same prognostic factors used for younger postmeno-
pausal women drive the therapeutic choices made by 
physicians.
 As chronologic and biologic age may differ, a multidi-
mensional geriatric assessment (MGA) is increasingly be-
ing used to select patients according to functional and 
cognitive status, comorbidity and social and logistic lim-
itations in order to identify frail subjects who should rath-
er be treated only with supportive care  [20] .
 The aim of this study was to retrospectively evaluate 
the safety of trastuzumab-based regimens in older wom-
en with early, locally advanced and/or metastatic HER2-
positive breast cancer.
 Methods 
 We reviewed data between 2005 and 2010 of HER2-overex-
pressing breast cancer patients referred to two Sicilian oncology 
centers. Patients were eligible for this study if they met the follow-
ing criteria: (1) female and aged  ≥ 70 years, (2) a histological diag-
nosis of breast cancer (stage I–IV according to the TNM (tumor 
size, node, metastasis) American Joint Committee on Cancer ver-
sion VI), (3) HER2-positive status determined using Hercept Test 
(DAKO) with a 3+ result on immunohistochemistry (IHC) or a 2+ 
IHC result and a positive result using fluorescence in situ hybrid-
ization (FISH), (4) patients had previously undergone surgery, ra-
diation treatment of the chest wall, hormonotherapy and CT (an-
thracycline-based or others), (5) availability of local staging and 
biological parameters: pT (tumor size), pN (nodal status), histo-
logical grade (G), ER (estrogen receptor), PgR (progestin receptor) 
and Ki67 (proliferative index); the ER and PgR status was defined 
as positive if cell staining was  ≥ 10% by IHC, (6) patients were re-
quired to have adequate cardiac function evaluated by echocar-
diography (left ventricular ejection fraction, LVEF  ≥ 50%), (7) an 
Eastern Cooperative Oncology Group (ECOG) performance sta-
tus of 0–2, (8) adequate hematologic, hepatic and renal function 
and (9) MGA based on Balducci’s criteria  [20] . Patients were ex-
cluded if they had a prior history of uncontrolled arrhythmia and/
or significant cardiac disease. Prior trastuzumab therapy was also 
not allowed. Each subject gave a written informed consent to the 
study, and the study was approved by the institutional ethical com-
mittee.
 Trastuzumab was administered every 3 weeks (as a 8 mg/kg 
loading dose followed by 6 mg/kg) or weekly (as a 4 mg/kg loading 
dose followed by 2 mg/kg). In both regimens, trastuzumab was in-
fused in 250 ml of normal saline, for over 90 min for the first dose 
and 60 min for the subsequent doses. Trastuzumab given in asso-
ciation with CT was administered on the first day of each cycle. 
Patients received corticosteroid premedication (dexamethasone, 
either 8 mg or 4 mg i.v.) for at least the first 3 weeks of trastuzum-
ab administration.
 Safety was assessed by changes in physical, hematologic and 
cardiologic findings.
 A functional and cardiologic assessment by clinical history, 
physical examination, MGA, blood chemistry, electrocardiogram 
and echocardiogram-determined LVEF was performed before 
starting therapy and then every 3 months and with the occurrence 
of symptoms or signs suspicious for cardiac dysfunction. Adverse 
events were graded according to the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC). Cardiac dysfunction was 
defined as congestive heart failure (CHF), cardiomyopathy or a 
LVEF decrease of at least 10%.
 Results 
 We examined 59 consecutive HER2-positive breast 
cancer patients aged  ≥ 70 years and their main clinical-
pathological characteristics are described in  table 1 . The 
mean age was 76 years (range 70–86 years). Histological 
types included 51 ductal, 5 lobular, 2 medullary and 1 mu-
cinous invasive carcinoma. Determination of receptor 
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status showed ER-negative/PgR-negative disease in 25 
patients (42.3%), ER-positive/PgR-positive disease in 19 
patients (32.2%), ER-positive/PgR-negative disease in 12 
patients (20.3%) and ER-negative/PgR-positive disease in 
3 patients (5.0%). HER2 positivity was determined by 
IHC in 44 patients and by FISH in 15 patients.
 ECOG performance status was 0 in 27 patients (45.8%), 
1 in 20 patients (33.9%) and 2 in 12 patients (20.3%).
 The following comorbidities were identified in 46/59 
(77.9%) patients: mild to moderate hypertension (n = 19, 
41.3%), diabetes (n = 12, 26.08%), hypothiroidism (n = 5, 
10.86%), osteoporosis (n = 6, 13.04%), obesity (n = 3, 
6.52%), hypercholesterolemia (n = 4, 8.69%), depression 
(n = 3, 6.52%), rheumatoid arthritis (n = 1, 2.17%) and 
thrombophlebitis (n = 1, 2.17%). In 28 patients (60.89%) 
1 comorbidity was identified, 2 were identified in 15 pa-
tients (32.60%) and 11 patients (23.91%) were found to 
have  ≥ 3 concomitant comorbidities.
 Among the 59 cases reviewed, baseline MGA was per-
formed in 48 patients (81.3%), according to which 20 
(41.7%) were classified as fit and 28 (58.3%) as unfit, 22 
as vulnerable (22/28, 78.5%) and 6 as frail (6/28, 21.4%). 
Eleven patients were treated without a baseline MGA, but 
a careful evaluation of general conditions and comorbid-
ities was taken into consideration. Trastuzumab was not 
administered in frail patients as well as in 2 patients who 
had not had an MGA but presented with important co-
morbidities.
 Overall, 51 of the 59 patients received trastuzumab , 
alone or combined with cytotoxic or hormonal agents, 
and all were valuable for safety ( table 2 ,  3 ). Eighteen pa-
tients presented with early-stage, 3 with locally advanced 
disease, and 30 with metastatic disease. Median treat-
ment duration was 12.0 months with a range of 4–41 
months. Thirty-six (70.5%) of 51 evaluable patients had 
been pretreated with CT, 16 (44.4%) had received non-
anthracycline-containing regimens and 20 (55.5%) had 
received anthracyclines (11 received epirubicin and 9 re-
ceived liposomal doxorubicin). Previous thoracic radio-
therapy was performed in all patients presenting with 
early-stage disease. Trastuzumab as a single agent was 
administered to 9 patients (17.6%), 6 of whom had met-
astatic disease. Trastuzumab plus hormonotherapy (aro-
matase inhibitors) was administered to 19 patients 
Table 1.  The main characteristics of consecutive HER2-positive 
BC patients aged ≥70 years
BC Number %
Total 59
Patients evaluable 51 86.4
Median age, years (range) 76 (70–86)
Early-stage 18 35.3
Locally advanced 3 5.9
Metastatic 30 58.8
ECOG performance status
0 27 45.8
1 20 33.9
2 12 20.3
MGA 48 81.3
Fit 20 41.7
Unfit 28 58.3
Comorbidities 46/59 77.9
Hypertension 19/46 41.3
Diabetes 12/46 26.08
Hypothyroidism 5/46 10.86
Obesity 3/46 6.52
Hypercholesterolemia 4/46 8.69
Depression 3/46 6.52
Thrombophlebitis 1/46 2.17
Rheumatoid arthritis 1/46 2.17
Osteoporosis 6/46 13.04
Table 2.  Previous CT and/or radiotherapy and trastuzumab regi-
mens in elderly BC patients
Number %
Trastuzumab monotherapy 9/51 17.6
Trastuzumab + hormonotherapy 19/51 37.3
Trastuzumab + CT 23/51 45.1
CT pretreatment 36/51 70.5
Anthracyclines 20/36 55.5
Non-anthracyclines 16/36 44.4
Previous RT (thoracic wall) 18/36 35.3
Table 3.  Type of toxicity in elderly BC patients treated with trastu-
zumab-based regimens
Type Number %
Hypersensitivity 3 5.9
Cardiotoxicity
Reduction FEVS >10% 3 5.9
Reduction FEVS >15% 3 5.9
CHF 1 1.9
Median basal LVEF 61
Range 52–76
Median final LVEF 55
Range 40–65
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(37.3%), while trastuzumab in combination with CT was 
administered to 23 patients (45.1%): 8 received concom-
itant taxanes, 11 received vinorelbine and 4 received 
gemcitabine ( table 2 ).
 Mild to moderate hypersensitivity reactions associated 
with trastuzumab-containing infusions occurred in 3 pa-
tients (5.9%), including 2 cases of chills and fever that re-
solved after the administration of a 3-weekly trastuzumab 
loading dose, and 1 case of a chill.
 No case of a severe reaction requiring the interrup-
tion of trastuzumab infusion was observed. These events 
were all of short duration (i.e. resolved by slowing the 
infusions) and did not reappear during the subsequent 
cycles.
 In all patients, the median baseline LVEF was 61% 
(range 52–76%), and the median final LVEF was 55% 
(range 40–65%) ( table 3 ). The majority cardiac events re-
lated to or likely to be ascribed to trastuzumab occurred 
in patients given concurrent CT: a total of 7 cases.
 A case of symptomatic CHF occurred when navelbine 
given in combination with trastuzumab which required 
treatment withdrawal appeared during cycle 5 in a 
78-year-old patient with a history of mild hypertension 
on therapy with an ACE inhibitor, who had had a recur-
rence after epirubicin-based adjuvant CT without radio-
therapy. This woman experienced exertion dyspnea, 
tachycardia and peripheral edema. Her LVEF decreased 
from the basal value of 54 to 37%. All symptoms and 
signs improved on treatment with ACE inhibitors plus 
diuretics and β-blockers, and LVEF was partially recov-
ered (up to 50%) within 17 weeks. No hospitalization was 
needed and her blood pressure was under control during 
this episode. Three patients who received aromatase in-
hibitors combined with trastuzumab developed asymp-
tomatic >15% decreases in LVEF <50%. They discontin-
ued trastuzumab-based treatment and initiated ACE in-
hibitors. After recovering the LVEF values, the same 
trastuzumab-based treatment was restarted, but 1 pa-
tient had a further 14% LVEF drop and therefore treat-
ment was withdrawn. In the other 3 cases, there was a 
>10% LVEF decrease that did not reach 50%. These pa-
tients continued the same trastuzumab-based treatment 
with no further declines.
 The median baseline LVEF of evaluated patients was 
61%, with a range of 52–76%. The median final LVEF was 
55%, with a range of 40–65% ( table 3 ).
 No substantial differences in the number or grade of 
adverse events were seen between patients who received 
trastuzumab once a week or every 3 weeks.
 Discussion and Conclusions 
 The lack of guidelines for elderly HER2-positive breast 
cancer shows that there is a need for clinical trials to ad-
dress the safety and efficacy of trastuzumab-based treat-
ments in a population who may have a substantially long 
life expectancy (about 15 years for a 70-year-old woman 
with an average health status, declining to 7 years for an 
85-year-old woman)  [21] and, consequently, a high risk 
of recurrence and death for this aggressive form of BC.
 The objective of this study was to evaluate the safety of 
trastuzumab as a monotherapy or in addition to CT or 
endocrine therapy in a 5-year series of consecutive HER2-
positive breast cancer patients aged  ≥ 70.
 The retrospective nature of the study limits our analy-
sis, but the collection of this large case-series with HER2-
overexpression is nevertheless one of the few studies 
aimed to assess the safety profile in elderly patients treat-
ed with trastuzumab-based regimens.
 Our results show that trastuzumab-based treatments 
were well-tolerated and adverse events were mild to mod-
erate in severity, with only 2 treatment withdrawals.
 Either mild or no side effects were observed in patients 
given trastuzumab alone or in combination with hor-
monotherapy. Hypertension and obesity as comorbidi-
ties, previous anthracycline treatment and CT combined 
with trastuzumab are associated with a higher incidence 
of development of various-grade cardiac toxicity. Infu-
sion-related side effects occurred mostly during the first 
trastuzumab administration, and their frequency and de-
gree were comparable with those described in various 
other studies  [22] .
 Advanced age is an important risk factor for cardiac 
events, as well as pre-existing cardiac dysfunction, base-
line LVEF  ≤ 50%, poorly controlled hypertension, anthra-
cycline pretreatment and previous radiotherapy to the left 
thoracic wall  [8] . Older patients with numerous associ-
ated chronic diseases are at higher risk of cardiotoxicity. 
Its severity varies from asymptomatic LVEF decreases to 
symptomatic CHF, which may be life-threatening  [23] .
 In about 80% of cases, it is reversible and responds to 
trastuzumab withdrawal and standard therapies for CHF 
 [24, 25] . In a multivariate analysis of two large studies, 
NSABP-B31 and NCCTG N-9831, age appeared to be a 
significant predictor for CHF in the combination arms 
 [13, 20, 21] . An analysis of the Herceptin Adjuvant 
(HERA) trial also showed a higher rate of age-related car-
diac events in the arm receiving trastuzumab plus CT, 
compared with CT alone (3.64 and 0.59%, respectively) 
 [12] . Subsequent to the introduction of trastuzumab-
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based treatments in the clinical practice, a certain liberal-
ization of the strict selection criteria utilized in the clinical 
trials has led to an increase of cardiotoxicity incidence, 
with 28% of patients being reported to experience a car-
diac event  [26, 27] . Cardiac events were seen in 2.6–4.5% 
of the patients treated with trastuzumab monotherapy, in 
13% of those on trastuzumab plus paclitaxel and in 27% 
in those on trastuzumab plus anthracyclines  [28, 29] .
 In our case-series, the incidence rate of CHF was 1 case 
in 51 patients (1.9%), below the cut-off of 4% that has 
been considered acceptable in clinical trials  [28, 29] . Fur-
thermore, cardiac adverse events were not affected by the 
number of trastuzumab administrations, consistent with 
the cardiotoxicity data generally reported for this drug 
 [22] . Moreover, when trastuzumab was combined with 
CT, it showed a manageable toxicity, with an incidence 
rate that did not exceed the ranges observed in studies on 
women <70 years old  [27] .
 Several observations need to be expressed about our 
favorable safety results. First, the reduced number of an-
thracycline-containing pretreatments (n = 20, 55.5%) as 
well as the frequent employment of liposomal formula-
tions might have resulted in a lesser incidence of cardiac 
events. Secondly, a substantial percentage of patients were 
selected on the basis of MGA; this tool spares frail patients 
from receiving potentially toxic drugs and, in our case, it 
allowed physicians to offer trastuzumab-based treatments 
to more than three quarters of the patients. Finally, close 
patient monitoring allowed precocious therapeutic inter-
ventions in the cases of cardiac dysfunction. So our data 
found a good correlation with some recent reports where 
the patients were treated with trastuzumab as an adjuvant 
modality and in other limited cases  [8, 30–32] .
 Our results are consistent with those of a recent paper 
published by Serrano et al. [33] . In older patients, cardio-
vascular risk factors and previous CT treatments are the 
most important factors in the development of trastuzum-
ab-related cardiotoxicity. So age does not exclude trastu-
zumab-based therapy in this class of patients.
 A recent paper published by Brollo et al.  [34]  analyzed 
the role of trastuzumab in elderly patients in an adjuvant 
setting. However, these data can not be compared with 
our results because this work included patients >60 years 
old whereas we refer to a population of >70 years old. 
They also analyzed the role of trastuzumab-based therapy 
only in an adjuvant setting whereas we evaluated the safe-
ty of trastuzumab in an adjuvant and a metastatic setting.
 In conclusion, our data show a good safety profile of 
trastuzumab in nonfrail women aged  ≥ 70 years. Future 
multicenter prospective trials should address both the 
early and metastatic stages in this high-risk age group and 
include selection criteria such as a geriatric assessment. 
Such trials should provide algorithms of optimal risk-
benefit for trastuzumab-based treatments  [7, 35, 36] .
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